Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Mohamed Hassan Sayegh, M.D.

Co-Author

This page shows the publications co-authored by Mohamed Sayegh and Paolo Fiorina.
Connection Strength

3.303
  1. Role of podocyte B7-1 in diabetic nephropathy. J Am Soc Nephrol. 2014 Jul; 25(7):1415-29.
    View in: PubMed
    Score: 0.571
  2. B cell-targeted therapies in autoimmunity: rationale and progress. F1000 Biol Rep. 2009 May 28; 1:39.
    View in: PubMed
    Score: 0.409
  3. Targeting CD22 reprograms B-cells and reverses autoimmune diabetes. Diabetes. 2008 Nov; 57(11):3013-24.
    View in: PubMed
    Score: 0.387
  4. P2X7R mutation disrupts the NLRP3-mediated Th program and predicts poor cardiac allograft outcomes. J Clin Invest. 2018 08 01; 128(8):3490-3503.
    View in: PubMed
    Score: 0.192
  5. Interleukin-10+ regulatory B cells arise within antigen-experienced CD40+ B cells to maintain tolerance to islet autoantigens. Diabetes. 2015 Jan; 64(1):158-71.
    View in: PubMed
    Score: 0.147
  6. TIM4 Regulates the Anti-Islet Th2 Alloimmune Response. Cell Transplant. 2015; 24(8):1599-1614.
    View in: PubMed
    Score: 0.142
  7. Effect of the purinergic inhibitor oxidized ATP in a model of islet allograft rejection. Diabetes. 2013 May; 62(5):1665-75.
    View in: PubMed
    Score: 0.131
  8. Long-term heart transplant survival by targeting the ionotropic purinergic receptor P2X7. Circulation. 2013 Jan 29; 127(4):463-75.
    View in: PubMed
    Score: 0.131
  9. Inotuzumab ozogamicin murine analog-mediated B-cell depletion reduces anti-islet allo- and autoimmune responses. Diabetes. 2012 Jan; 61(1):155-65.
    View in: PubMed
    Score: 0.121
  10. IL-21 is an antitolerogenic cytokine of the late-phase alloimmune response. Diabetes. 2011 Dec; 60(12):3223-34.
    View in: PubMed
    Score: 0.121
  11. Targeting the CXCR4-CXCL12 axis mobilizes autologous hematopoietic stem cells and prolongs islet allograft survival via programmed death ligand 1. J Immunol. 2011 Jan 01; 186(1):121-31.
    View in: PubMed
    Score: 0.114
  12. A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice. Diabetes. 2010 Sep; 59(9):2253-64.
    View in: PubMed
    Score: 0.112
  13. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol. 2009 Jul 15; 183(2):993-1004.
    View in: PubMed
    Score: 0.103
  14. Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes. 2008 Jul; 57(7):1759-67.
    View in: PubMed
    Score: 0.096
  15. Phenotypic and functional differences between wild-type and CCR2-/- dendritic cells: implications for islet transplantation. Transplantation. 2008 Apr 15; 85(7):1030-8.
    View in: PubMed
    Score: 0.095
  16. Role of ICOS pathway in autoimmune and alloimmune responses in NOD mice. Clin Immunol. 2008 Feb; 126(2):140-7.
    View in: PubMed
    Score: 0.091
  17. Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Clin Immunol. 2007 Oct; 125(1):16-25.
    View in: PubMed
    Score: 0.090
  18. Characterization of donor dendritic cells and enhancement of dendritic cell efflux with CC-chemokine ligand 21: a novel strategy to prolong islet allograft survival. Diabetes. 2007 Apr; 56(4):912-20.
    View in: PubMed
    Score: 0.087
  19. Role of CXC chemokine receptor 3 pathway in renal ischemic injury. J Am Soc Nephrol. 2006 Mar; 17(3):716-23.
    View in: PubMed
    Score: 0.081
  20. CD160Ig fusion protein targets a novel costimulatory pathway and prolongs allograft survival. PLoS One. 2013; 8(4):e60391.
    View in: PubMed
    Score: 0.033
  21. Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes. Diabetes. 2010 Dec; 59(12):3139-47.
    View in: PubMed
    Score: 0.028
  22. Beta 3 integrins regulate lymphocyte migration and cytokine responses in heart transplant rejection. Am J Transplant. 2007 May; 7(5):1080-90.
    View in: PubMed
    Score: 0.022
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.